Jeanelle Tyson, Buyer

Jeanelle Tyson serves as a Buyer within the FDA Office of Acquisition and Grant Services, where she plays a critical role in securing specialized analytical instrumentation and laboratory support services essential to the agency’s regulatory science mission. Her procurement activities focus on maintaining high-precision equipment used in drug safety testing, biological product analysis, and medical device evaluation. She manages the full lifecycle of acquisitions—from market research and requirement definition to contract award and performance monitoring—ensuring alignment with federal acquisition regulations and FDA’s scientific priorities. Her work directly enables the agency’s ability to uphold public health standards through reliable, cutting-edge laboratory capabilities. Tyson maintains consistent working relationships with a select group of specialized vendors, including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc, and Progenics Pharmaceuticals Inc, all of which provide niche scientific and analytical support services. These partnerships are characterized by deep technical alignment, repeat engagement, and a focus on mission-critical expertise in toxicology, clinical research, and pharmaceutical analysis. Her contracting patterns reflect a preference for established contractors with proven track records in regulated environments, ensuring continuity and compliance in high-stakes scientific operations. Tyson’s procurement portfolio is entirely non-set-aside, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on accessing the broadest possible pool of technically qualified vendors capable of meeting the FDA’s rigorous scientific and regulatory standards, rather than prioritizing socioeconomic categories. While small business participation is not formally targeted, her acquisitions remain accessible to all qualified firms that meet stringent technical and quality requirements. Her primary procurement focus is centered on NAICS 334516—Analytical Laboratory Instrument Manufacturing—where she acquires advanced mass spectrometers, chromatography systems, and other high-end analytical platforms critical to FDA’s laboratory operations. Her domain expertise lies in procuring complex, calibrated instruments used in pharmacokinetic studies, contaminant detection, and quality control testing, requiring deep technical understanding of regulatory compliance and instrument validation protocols.